SCHEMBL7603669

SCHEMBL7603669

c1ccc(CNCC2CCCCC2)cc1

nearest known ligand 0.63

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CXCR4 P61073 3/20 0.63
NPC1 O15118 1/20 0.63
RAB9A P51151 1/20 0.63
SIGMAR1 Q99720 1/20 0.61
HDAC6 Q9UBN7 2/20 0.59
HDAC3 O15379 1/20 0.54
HDAC4 P56524 1/20 0.54
HDAC1 Q13547 1/20 0.54
HDAC8 Q9BY41 1/20 0.54
HDAC5 Q9UQL6 1/20 0.54
EPHX2 P34913 2/20 0.51
HTT P42858 1/20 0.51
ESRRA P11474 1/20 0.51
EPHX1 P07099 2/20 0.50
HTR2C P28335 1/20 0.50
HPGD P15428 1/20 0.50
MAN1B1 Q9UKM7 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10764797 1.00 CXCR4 (0.63) CXCR4NPC1RAB9ASIGMAR1HDAC6
Hydrochloric Acid SCHEMBL31169762 0.98 CXCR4 (0.61) CXCR4NPC1RAB9ASIGMAR1HDAC6
SCHEMBL10349210 0.98 CXCR4 (0.65) CXCR4NPC1RAB9ASIGMAR1HDAC6
SCHEMBL23023087 0.94 CXCR4 (0.65) CXCR4NPC1RAB9ASIGMAR1HDAC6
Decarboxylated Derivative SCHEMBL25372998 0.92 SIGMAR1 (0.57) CXCR4NPC1RAB9ASIGMAR1HDAC6
SCHEMBL2934330 0.90 CXCR4 (0.69) CXCR4NPC1RAB9ASIGMAR1HDAC6
SCHEMBL16083006 0.90 CXCR4 (0.69) CXCR4NPC1RAB9ASIGMAR1HDAC6
SCHEMBL18096446 0.87 CXCR4 (0.57) CXCR4NPC1RAB9ASIGMAR1HDAC6
SCHEMBL8826390 0.85 HTT (0.58) CXCR4NPC1RAB9ASIGMAR1HDAC6
SCHEMBL8493195 0.83 ALDH1A1 (0.56) CXCR4NPC1RAB9ASIGMAR1HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250136594-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2025-05-01 US disclosed
CN-118956250-B High-strength high-weather-resistance elastic coating and preparation method and application thereof 天津森聚柯密封涂层材料有限公司 2025-01-03 CN disclosed
EP-4469438-A1 COMPOUNDS AND METHODS OF USE Tango Therapeutics, Inc. (US) 2024-12-04 EP disclosed
CN-118956250-A High-strength high-weather-resistance elastic coating and preparation method and application thereof 天津森聚柯密封涂层材料有限公司 2024-11-15 CN disclosed
CN-118834594-A Single-component elastic coating and preparation method and application thereof 沧州渤海新区高内聚能化工有限公司 2024-10-25 CN disclosed
US-20240051974-A1 DIRECT REDUCTIVE AMINATIONS WITH MONOTRIFLUOROACETOXY BORANE-AMINES PURDUE RESEARCH FOUNDATION (US) 2024-02-15 US disclosed
WO-2023209336-A1 ANTI-INFECTIVE AGENTS UNIVERSITY OF DUNDEE (GB) 2023-11-02 WO disclosed
WO-2023146987-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. (US) 2023-08-03 WO disclosed
WO-2023146987-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. (US) 2023-08-03 WO disclosed
CN-115433508-B Single-component high-strength elastic coating and preparation method and application thereof 天津森聚柯密封涂层材料有限公司 2023-04-18 CN disclosed
EP-0661283-A1 BRAIN CELL PROTECTIVE TORAY INDUSTRIES, INC. (JP) 1995-07-05 EP disclosed
US-5391808-A Lubricant and synthetic polymer additives for heat and oxidation resistance CIBA-GEIGY CORPORATION (US) 1995-02-21 US disclosed
EP-0585202-A1 N,N'-alkenylene amine/mercaptotolyl-imidazole blends as high temperature antioxidants for elastomers CIBA-GEIGY AG (CH) 1994-03-02 EP disclosed
US-5283367-A Antioxidants for lubricants and polymers CIBA-GEIGY CORPORATION (US) 1994-02-01 US disclosed
US-5240976-A For automobile, wire and cable uses CIBA-GEIGY CORPORATION (US) 1993-08-31 US disclosed
EP-0514333-A2 Substituted 1,4-diamino-2-butene stabilizers and stabilized compositions CIBA-GEIGY AG (CH) 1992-11-19 EP disclosed
US-4503249-A ORGANIC COMPOUNDS PHILLIPS PETROLEUM COMPANY (US) 1985-03-05 US disclosed
US-4401640-A IRON II HEXACYANOCOBALTATE PHILLIPS PETROLEUM COMPANY (US) 1983-08-30 US disclosed
US-4394298-A RUTHENIUM/III/ HEXACYANOCOBALTATE, SUPPORT PHILLIPS PETROLEUM COMPANY (US) 1983-07-19 US disclosed
US-4163025-A Process for the production of benzylamine and dibenzylamine MILES LABORATORIES, INC. (US) 1979-07-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250136594-A1 COMPOUNDS AND METHODS OF USE CNKSR1, UGT1A1, REV1 CXCR4 424/4885NPC1 1403/4885RAB9A 190/4885
US-20240051974-A1 DIRECT REDUCTIVE AMINATIONS WITH MONOTRIFLUOROACETOXY BORANE-AMINES MAOB, BCAT2, AADAT CXCR4 4067/4885NPC1 3012/4885RAB9A 3334/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.